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Meibomian glands (MGs) play a crucial role in the ocular surface homeostasis by providing lipids to the superficial tear film.Their
dysfunction destabilizes the tear film leading to a progressive loss of the ocular surface equilibrium and increasing the risk for dry
eye. In fact, nowadays, the meibomian gland dysfunction is one of the leading causes of dry eye. Over the past decades, MGs have
beenmainly studied by usingmeibography, which, however, cannot image the glandular structure at a cellular level.The diffusion of
the in vivo laser scanning confocal microscopy (LSCM) provided a new approach for the structural assessment of MGs permitting
a major step in the noninvasive evaluation of these structures. LSCM is capable of showingMGsmodifications during aging and in
themost diffuse ocular surface diseases such as dry eye, allergy, and autoimmune conditions and in the drug-induced ocular surface
disease. On the other hand, LSCMmay help clinicians in monitoring the tissue response to therapy. In this review, we summarized
the current knowledge about the role of in vivo LSCM in the assessment ofMGs during aging and in the most diffuse ocular surface
diseases.
1. Introduction
Meibomian glands (MGs) are holocrine glands embedded
in the tarsal plate of the eyelids. Each gland comprises
multiple acini connected by a long common central duct
running throughout the entire length of the gland [1]. The
functional unit of a meibomian gland is the meibocyte,
which synthesizes the meibum, a lipoid complex forming
the superficial layer of the tear film. Meibum permeates the
tear surface where it serves several important functions: it
prevents tear evaporation and desiccation of the ocular sur-
face, acts as a physical and hydrophobic barrier to the inward
movement of environmental and organic agents, lubricates
the ocular surface preventing irritation, and promotes clear
ocular vision due to its optic properties.Thus, tear physiology
is dependent upon the proper functioning of the MGs [2, 3].
Meibography represented for many years the only diag-
nostic approach to observe the MGs morphology in vivo [4].
With the recent diffusion of the laser scanning confocal
microscopy (LSCM) (HRT I–III Rostok Cornea Module
(RCM), Heidelberg Engineering, Heidelberg, Germany), it
was possible to study the microscopic anatomy of several
adnexal and ocular surface structures such as eyelid, con-
junctiva, cornea, limbus, tarsal plate, and MGs [5–12]. LSCM
allows integrated high-resolution evaluation of the morpho-
functional ocular surface unit in normal and pathological
conditions [13]. Several conditions may affect the anatomy
and function of MGs, such as the primary meibomian gland
dysfunction, dry eye, ocular allergy, the use of contact lenses,
and the long-term application of topical medications in
chronic ocular surface diseases and in glaucoma. In this
review, we discuss the main MGs modifications during aging
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Figure 1: LSCM of MGs in two healthy Caucasian subjects. (a) A 26-year-old male with a normal feature and density of the acini (asterisks);
(b) a 73-year-old male with decreased MG acinar density and increased acinar size (arrow), indicative of atrophic age-related changes. Bar
represents 50 𝜇m.
and during the course of the most diffuse ocular surface
diseases.
2. Methodology and Results
PubMed searches were performed on September 20, 2015,
using the following phrases: “in vivo confocal microscopy”
and “meibomian glands”, which identified thirty-four unique
publications. Six were excluded, since they did not concern
the use of IVCM to study MGs.
Three of the considered publications were not published
in English; however, they provided enough information in the
English abstract to warrant inclusion.
2.1. Meibomian Glands in the Healthy and Aging Human
Eye. The confocal images are captured from a coronal scan
through a mass of acini posterior to a central, vertically ori-
entedMGduct [14]. LSCMprovides structural and functional
information of the glandular status: MGs acini appear to be
constituted by convoluted borders with large cells lining the
acini and fine cellular material within the lumen [14].
Themain structural modifications induced by aging were
evidenced for the first time by Wei et al. [15] and afterwards
confirmed by Villani et al. [16] in a heterogeneous popula-
tion study, which revealed significant negative correlations
between age and meibomian glandular acinar unit density
[1]. LSCM permits indirect functional evaluation of MGs, by
assessing the secretion reflectivity [4].
Besides the acinar density reduction, the normal aging
induces also an evident decrease of the acinar diameter
(Figure 1) and an increase of the acinar wall inhomogeneity,
without significant modifications of the glandular orifice
diameter. The overall interpretation of the structural modi-
fication suggests glandular dropout with qualitative changes
of the meibum. Therefore, the authors speculated that acinar
atrophy leads to a decrease in the MGs secretion with aging.
These results are in accordance with themain clinical changes
observed during aging, represented by tear film break-up
time (BUT) and Schirmer test scores reduction.
Even though several studies reported likely hormone-
dependent changes of MGs structure [17–19], LSCM did not
document significant structural and functional differences
between genders during aging [19, 20]. Further studies
are warranted to elucidate the clinical implications of the
hormonal action on MGs age-related changes.
In summary, LSCM in healthy subjects provides infor-
mation of the normal modifications of glands with aging.
Normal aging induces atrophic involution of the glandular
unit along with progressive dysfunction of the secretive
activity (Table 1).This appears to be in linewith the involution
of most parts of secretive structures, such as exocrine glands
and lymphatics, observed in several tissues of the human
body during aging [21–23]. In the eye, the glandular unit
involution may take part in the increased risk of dry eye
related conditions observed in the elderly.
2.2. Primary and Secondary Meibomian Glands Dysfunction.
The primary meibomian gland dysfunction (MGD), charac-
terized by inflammatory changes of the lid margin structures
and in the anatomy of the MG orifices, is one of the most
common ocular surface disorders: Hom et al. [20] reported
prevalence of 38.9%, whereas Stanek [41] reported prevalence
of 71.7% in individuals above 60 years old. MGD is a major
cause of dry eye and results in a qualitative alteration and/or
a quantitative reduction of the lipid secretion, which leads
to decreased tear stability, increased tear evaporation, loss
of lubrication, and damage to the ocular surface epithelia.
LSCM, which currently has a primary role in the ocular
surface analysis [26, 27], allows studying MG at cellular level.
In MGD, LSCM permits the analysis of the cellular density
of the superficial and basal epithelium of the eyelid and the
assessment of the mean acinar area and density of MGs,
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Table 1: Summary of the most important confocal signs for each disease affecting MGs.
Conditions LSCM characteristics References
Aging MG acinar unit density and diameter reduction;increase of the acinar wall inhomogeneity
[13, 15, 16, 24,
25]
MGD MG acinar unit density reduction;larger acinar unit diameter; duct dilation [26–31]
Dry eye
MG acinar unit density and diameter reduction;
inhomogeneous appearance of the MG walls and
interstices;
extensive periglandular Langerhans cell infiltration
[13, 16, 24, 25,
32–35]
Ocular allergy
Eosinophils and multinucleated granulocytes in the
superficial conjunctival epithelium; periglandular
lymphocytic cell infiltration; glandular atrophy and
acinar and ductal dilatation
[13, 16, 24, 25,
36–39]
Glaucoma
MG acinar unit density and area reduction; increased
reflectivity of the acinar secretion; ductal orifice
dilation; inhomogeneity of MG interstice and wall
[9, 40]
the glandular orifice area, the meibum secretion reflectivity,
and the inflammatory features of periglandular interstices
and acinar unit wall (patterns of inhomogeneity) [40]. In
the first confocal study on MG diseases, Messmer et al. [28]
showed dilatation and obstruction of the meibomian gland
ducts in twelve patients with blepharitis/meibomitis orMGD.
On the other hand, in fifteen out of 19 patients with ble-
pharitis/meibomitis, but not in MGD, intense inflammation
was observed in the tarsal conjunctival epithelium and in
the stroma. The inflammatory reaction was defined by an
increase of hyperreflective roundish elements corresponding
to immune cells.Matsumoto et al. [29] reported that themean
acinar unit density was significantly lower in MGD patients
than in control subjects, whereas the mean acinar unit
diameter was significantly larger in MGD patients than in
controls. Both the density and diameter of MGs acinar units
significantly correlated with the severity of MGs dropout and
expression grades (Figure 3).
Other confocal parameters that presented acceptable
sensitivity and specificity for the diagnosis of MGD were the
longest and shortest MG diameters: in the study of Ibrahim
et al., these parameters resulted to be significantly worse
than those observed in the controls [30]. As stated above,
LSCM can also provide information about the inflammatory
status of MG during MGD. Matsumoto et al. [42] measured
the mean inflammatory cell density (cells/mm2) from the
periglandular site of the entire lower and upper eyelid,
reporting inflammatory cell numbers approximately ten to
thirty times higher than those found in healthy controls.
Interestingly, these cells markedly reduced after medical
therapy: the combination of lid hygiene, topical nonpreserved
artificial tears with 0.1% sodium hyaluronate, topical 0.5%
levofloxacin and 0.1% fluorometholone, and oralminocycline
(100mg twice a day for 12 weeks) significantly improved
the tear stability, the fluorescein staining scores, and the lid
injection and cleared periglandular inflammatory infiltrates.
In a very recent study, LSCM revealed an increased
immune cell number in the palpebral conjunctiva of patients
with refractory MGD, compared to patients with therapy-
responding MGD [43]. In the therapy-responding group,
the mean inflammatory cell density in the periglandular
area reduced from baseline values of 1216 ± 328 to 700 ±
436 cells/mm2 at the last follow-up. No statistically signifi-
cantly difference was found in the group that did not receive
any therapy, 882 ± 301 cells/mm2 before the initiation of trial
and 843 ± 321 cells/mm2 at the final follow-up.
Interestingly, OSDI scores correlated with epithelial
immune cells infiltrating the palpebral conjunctiva, sug-
gesting that the inflammation of the palpebral conjunctiva
may contribute to explaining the MGD-associated refractory
symptoms.
SecondaryMGD can develop as a complication of the use
of topical medications in patients with glaucoma [44–46] and
in contact lens wearers (CLWs) (Figure 2) [32].
In CLWs, a decreased basal epithelium cell density,
reduced acinar unit diameters, higher glandular orifice diam-
eters, greater secretion reflectivity, and greater inhomogene-
ity of the periglandular interstices were the main observed
findings. Morphologic changes in the MGs shown by LSCM
were interpreted by the authors as signs ofMGs dropout, duct
obstruction, and glandular inflammation caused by chronic
mechanical contact lens irritation.
In summary,MGDhas a huge impact on the daily clinical
practice since it plays a major role in the development of
dry eye related conditions. Confocal microscopy precisely
depicts, at a cellular level, the main macroscopic and micro-
scopic MGs changes in patients affected with both primary
and secondary MGD. The main features are represented
by the MGs dropout, which is the glandular unit loss, the
increase of the acinar surface (except for glaucoma), which,
along with the increased meibum viscosity, is the hallmark
of the glandular malfunction, and the inflammation of the
periglandular interstice and acinar wall. The dilation of
the duct orifice and the increased acinar diameter are the
compensatorymechanismadopted by the glands to overcome
the meibum stagnation (Table 1). All these changes lead to a
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Figure 2: LSCM of MGs in a contact lens wearer. The most
evident modifications are represented by the inhomogeneity of
periglandular interstices (asterisk) and MG wall (arrow), periglan-
dular inflammation, and the reduction of MG duct diameters. Bar
represents 50 𝜇m.
∗
Figure 3: Confocal microscopy features in a 47-year-old male
patient with MGD: inhomogeneity of periglandular interstices
(asterisk) and MG wall (arrow), dilation and obstruction of the MG
ducts, and reduction of the density of MG acinar units are the most
significant alterations. Bar represents 50 𝜇m.
decrease of the meibum production, which negatively affect
the tear film stability and induce dry eye.
Therefore, MGD could be in part intended as accelerated
aging of the glands, in which there is a marked inflammatory
and immune component. Also, these aspects are shared by
other exocrine glands’ dysfunction in the human body, such
as salivary glands [21–23].
In this field, confocal microscopy may provide a signifi-
cant advancement in the daily clinical practice since it helps
clinicians in the early diagnosis of primary or secondary
MGD and inmonitoring the response to therapy and the side
effects of drugs.
In fact, as recently reported in a study that evaluated the
efficacy of wet chamber warming goggles (Blephasteam) in
MGD patients unresponsive to warm compress treatment,
∗
Figure 4: LSCM of MGs in a patient with dry eye: the image shows
a decreased diameter of meibomian gland ducts, along with marked
inhomogeneous appearance of theMGwalls and interstices. Several
punctate hyperreflective elements, which reflect a high degree of
local inflammation, are recognizable in the interstice and within the
MG wall (arrow and asterisk). Bar represents 50𝜇m.
LSCM documented a decreased acinar diameter and area,
which was associated with an increased OSDI score [38].
2.3. Meibomian Glands in Dry Eye. Dry eye syndrome (DES)
is one of the most common disorders of the eye, with
prevalence of 10% to 20% in the adult population. The
International Dry Eye Workshop (2007) [47] defined DES
as a “multifactorial disease of the tears and ocular surface
that results in symptoms of discomfort, visual disturbance,
and tear film instability with potential damage to the ocular
surface. It is accompanied by increased osmolarity of the
tear film and inflammation of the ocular surface.” In this
field, LSCM documented the fine and peculiar microscopic
findings of the target tissues including the cornea, conjunc-
tiva, and meibomian glands. While several reports studied
the confocal corneal and conjunctival changes in DES, MGs
were only partially studied. In patients with primary DES
and MGD, Villani et al. [33] reported increased acinar
dilatation compared to primary DES and healthy controls,
higher meibum reflectivity, and decreased diameters of gland
orifices. Moreover, very interestingly, the authors showed
increased acinar density in primary DES (Figure 4). The
reduced lipid amount induces tear film hyperosmolarity,
which leads to tear film instability, increased evaporation,
and ocular surface inflammation [46]. A new integrated laser
scanning confocal microscopy approach recently found some
differences in the MGs features in patients with primary
Sjogren syndrome, non-Sjogren syndrome dry eye, andMGD
[32]. The pattern of inhomogeneity of the MGs walls and
interstices was markedly higher in all groups of patients
than in controls, with features more pronounced in primary
Sjogren syndrome compared to non-Sjogren syndrome dry
eye. The inhomogeneous appearance varies with the level of
inflammation that is significantly higher in eyes with Sjogren
syndrome, because of the autoimmune pathogenesis of this
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condition. The presence of confocal signs of inflammation
with the absence of dilative morphologic changes supports
the occurrence of an inflammatory/atrophic nonobstructive
MGD in the primary Sjogren syndrome [24, 33, 48].
Ban et al. [34] studied the morphological changes of MGs
in patients with dry eye due to chronic graft-versus-host
disease (GVHD), a major cause of morbidity and mortality
in patients undergoing allogeneic hematopoietic stem cell
transplantation for hematologic malignancies. They showed
that the acinar unit density and the longest and shortest
diameters of MGs acini are significantly decreased. Patients
with severe DES after chronic GVHD show glandular fibrosis
with MGs atrophy.
LSCM was also used to evaluate MGs modification in
allergic keratoconjunctival diseases, such as vernal and atopic
keratoconjunctivitis (VKC, AKC), whichmay frequently lead
to secondary dry eye [VZ, VW]. In VKC, extensive periglan-
dular Langerhans cell infiltration, with blurred lumen con-
tours and hyperreflective solid matter in the lumen, was
described [35, 39]. Ibrahim et al. [36] reported severe MGs
changes in patients with AKC, with extensive fibrotic changes
much more evident than that observed in MGD. These
patients present shrunken MGs with extensive periglandular
fibrosis, which does not allow gland enlargement as what
occurs in obstructive MGD [25].
In conclusion, in patients with dry eye, confocal
microscopy revealed that the inflammation is the first and
most important pathogenetic mechanism involved in the
development of the MG alterations. The main findings were
the increased acinar density and the reduced orifice diameter,
which differentiated DES from primary or secondary MGD
(Table 1). In this way, DES seems to lead to an incomplete
inflammatory-induced MGD. Other particular conditions
potentially leading to dry eye, such as VK, AK, and GHVD,
present also various degree of periglandular fibrotic reaction,
which finally causes MGs atrophy. In this wide scenario of
dry eye syndromes, LSCM may help clinicians in the early
diagnosis of each type of disease leading to dry eye and in
monitoring the response to therapy.
2.4. Meibomian Glands in Ocular Allergy. AKC and VKC
are two of the most common and important ocular allergies.
AKC is a bilateral chronic hypersensitivity disease character-
ized by conjunctival papillary hypertrophy, acute and chronic
conjunctivitis, keratitis and corneal ulceration, eyelid eczema,
and blepharitis [49–53]. Tears proinflammatory cytokines are
responsible for the conjunctival and corneal damage and also
for the MG alterations. MG changes play a critical role in the
development of the allergy-related dry eye [29].
VKC is a recurring seasonally inflammatory condition
of the cornea and conjunctiva, characterized by giant tarsal
papillae and pathological changes of the conjunctival epithe-
lium and MGs. LSCM documented intense infiltration of
eosinophils and multinucleated granulocytes in the super-
ficial conjunctival epithelium, extensive periglandular lym-
phocytic cells infiltration. These inflammatory alterations
lead to macroscopic modifications of MGs, represented by
glandular atrophy, and ductal dilation (Figure 5). The same
morphofunctional changes were described in ACK patients,
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Figure 5: Morphological changes of MGs in a 38-year-old female
patient with VKC: confocal microscopy shows extensive periglan-
dular mononucleate cell infiltration (arrow), acinar atrophy, and
ductal dilation, along with increased reflectivity of the acinar wall
(asterisk). Bar represents 50𝜇m.
where there is an important decrease in size and density
of MG acinar units. MGs appear small and irregular with
periglandular fibrosis and a restricted and not well-defined
lumen, occluded by hyperreflective and dense meibum [16,
31, 37, 54].
In allergic patients, the fibrotic involution of MG acinar
units is more extensive than that observed in obstructive
MGD, where the pressure induced by the stagnating meibum
induces enlargement of MG acini [29].
In summary, MG modifications in patients with ocular
allergy diseases are in part different from those observed in
MGD and dry eye, since the periacinar fibrosis, along with
the inflammatory infiltration and the meibum stagnation,
represents the main finding (Table 1). In these ocular surface
diseases, probably because of the periglandular compression
induced by the fibrosis and the intense inflammation, MGs
seem to be unable to activate adaptive mechanisms and
develop a progressive atrophy. At present, the small sample
size of research studies and poor standardization of examina-
tion and interpretation are the most challenging issues.
2.5. Meibomian Glands in Glaucoma. In the last years, LSCM
was also used to evaluate the impact of glaucoma therapy
on ocular surface structures [5–7, 55], including MGs [40].
In these studies, the modifications induced by the different
classes of topical medications, the impact of the preservative
and active compounds, and the role of the number of daily
instillations in patients in multitherapy have been investi-
gated.
MGs presented a reduction of glandular density and
area and increased reflectivity of the acinar secretion, more
evident in patients treated with two or more drugs compared
to patients in monotherapy. The reduced density and area
were expressions of glandular loss and reduced meibum pro-
duction, respectively. Higher secretion reflectivity indicated
increased secretion viscosity.
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Figure 6: LSCM of MGs in a glaucomatous patient in multitherapy.
The acinar unit density and area appeared to be reduced; MG wall
and periglandular interstice presented inhomogeneous appearance,
with some scattered hyperreflective punctate elements (arrowhead),
and increased density of the meibum (asterisk). Bar represents
50 𝜇m.
These modifications were similar to those observed in
patients with MGD, with the exception of the glandular area
that appeared to be reduced in glaucoma (Figure 6). Higher
secretion reflectivity could indicate increased meibum secre-
tion viscosity.
Other aspects characterizing MGs in glaucoma are the
ductal orifice dilation and the inflammation of the glandular
wall and interstice, which confocal microscopy documented
with the presence of punctate hyperreflective elements. The
ductal orifice dilation was probably an adaptive mechanism
to overcome the high secretion density and duct blockage
induced by treatment.
The potential induction mechanisms are the toxicity and
an inflammatory or immune-mediated response, with the
inflammation probably being the first step in the cascade of
glandular modifications [7, 12].
In patients in monotherapy LSCM contributed to clarify-
ing the role of preservatives (benzalkonium chloride (BAK))
and active compounds in the acinar modifications: preserved
drugs were more toxic than preservative-free (PF) formula-
tions, with preserved prostaglandin analogues (PGA) being
more toxic than preserved 𝛽-blockers. Therefore, BAK and
PGA, with their toxic and inflammatory stimuli, play the
most crucial role in the induction of glaucoma therapy-
related MGD.
Very interestingly, all the microscopic modifications of
MGs significantly correlated with the ocular surface disease
index (OSDI) score, break-up time (BUT), and Schirmer test
I (STI). These correlations indicated that MGs alterations,
as assessed with LSCM, were indicators of dry eye and
have a main role in development of the therapy-related
ocular surface disease in patients with glaucoma. Thus, the
preservation of the structural and functional integrity ofMGs
represents a critical challenge duringmedical management of
glaucoma.
In conclusion, the long-term antiglaucoma therapy has a
strong negative impact on MGs functionality: the iatrogenic
changes ofMGs, in fact, lead tomeibomian glanddysfunction
very similar to primary MGD, with the exception of the
reduced acinar area (Table 1). It is hypothesizable that toxicity
induces secondary meibomian gland dysfunction in which
glands are unable to activate processes that attempt to over-
come the secretion blockage. As a consequence, the acinar
size decreases andMGs progressively drop out.These features
are shared with CLWs, in which the mechanical trauma leads
to a secondaryMGD,with the exception of the reduced acinar
area. One may suppose that when the inflammation plays the
main role, MGs modify their features as in primary MGD,
whereas when toxic or mechanic stimuli play the main role,
MGs reduce also their size.
These modifications present evident clinical implications
since they could strongly affect adherence and persistence of
treatment.
3. Summary and Conclusions
Until recently, the microanatomy evaluation of the ocular
surface structures was limited to the impression cytology,
which is based on sampling the superficial epithelial layers.
This methodology, despite being highly reproducible, does
not allow exploring deep tissues and induces discomfort to
patients.
The rapid diffusion of LSCM in the last decades permitted
an in vivo biopsy of all ocular surface tissues, at different
depths, and the tissue analysis at cellular and subcellular level.
The meibomian gland is one of the ocular surface structures
that mostly benefited from the confocal assessment, since the
standard meibography can only give a macroscopic analysis
of the entire gland.The possibility of imagingMGs at cellular
level, in vivo, and in a noninvasive way permit studying these
structures in the most diffuse and important ocular surface
diseases such as dry eye, ocular allergy, and drug toxicity.
In this way, LSCM may allow a preclinical diagnosis
of MG conditions, potentially before glands begin to mal-
function. In addition, since confocal microscopy does not
produce significant discomfort for patients, this technique
offers the advantage to strictly monitor the disease over
time, to anticipate the treatment when required, to follow
the response to therapy, and to modify the therapy regimen
accordingly.
Moreover, the fine microscopic assessment could also
clarify the pathophysiology of these conditions. This is even
more important considering that the incidence of ocular
surface diseases is exponentially growing in the last years.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
Authors’ Contribution
Vincenzo Fasanella and Luca Agnifili equally contributed to
this work and share primary authorship.
BioMed Research International 7
References
[1] E. Knop, N. Knop, T. Millar, H. Obata, and D. A. Sullivan,
“The international workshop on meibomian gland dysfunc-
tion: report of the subcommittee on anatomy, physiology,
and pathophysiology of the meibomian gland,” Investigative
Ophthalmology and Visual Science, vol. 52, no. 4, pp. 1938–1978,
2011.
[2] S. Mishima and D. M. Maurice, “The oily layer of the tear film
and evaporation from the corneal surface,” Experimental Eye
Research, vol. 1, pp. 39–45, 1961.
[3] J. M. Tiffany, “The lipid secretion of the meibomian glands,”
Advances in Lipid Research, vol. 22, pp. 1–62, 1987.
[4] J. V. Jester, L. Rife, D. Nii, J. K. Luttrull, L. Wilson, and R. E.
Smith, “In vivo biomicroscopy and photography of meibomian
glands in a rabbit model of meibomian gland dysfunction,”
Investigative Ophthalmology and Visual Science, vol. 22, no. 5,
pp. 660–677, 1982.
[5] R. Mastropasqua, V. Fasanella, E. Pedrotti et al., “Trans-
conjunctival aqueous humor outflow in glaucomatous patients
treated with prostaglandin analogues: an in vivo confocal
microscopy study,” Graefe’s Archive for Clinical and Experimen-
tal Ophthalmology, vol. 252, no. 9, pp. 1469–1479, 2014.
[6] L. Agnifili, P. Carpineto, V. Fasanella et al., “Conjunctival
findings in hyperbaric and low-tension glaucoma: an in vivo
confocal microscopy study,” Acta Ophthalmologica, vol. 90, no.
2, pp. e132–e137, 2012.
[7] L. Mastropasqua, L. Agnifili, V. Fasanella et al., “Conjunctival
goblet cells density and preservative-free tafluprost therapy
for glaucoma: an in vivo confocal microscopy and impression
cytology study,” Acta Ophthalmologica, vol. 91, no. 5, pp. e397–
e405, 2013.
[8] L. Mastropasqua, M. Nubile, M. Lanzini et al., “Morphological
modification of the cornea after standard and transepithelial
corneal cross-linking as imaged by anterior segment optical
coherence tomography and laser scanning in vivo confocal
microscopy,” Cornea, vol. 32, no. 6, pp. 855–861, 2013.
[9] L. Agnifili, V. Fasanella, S. D’Aguanno et al., “Shotgun pro-
teomics reveals specific modulated protein patterns in tears of
patients with primary open angle glaucoma na¨ıve to therapy,”
Molecular BioSystems, vol. 9, no. 6, pp. 1108–1116, 2013.
[10] R. Mastropasqua, L. Agnifili, V. Fasanella et al., “Corneoscleral
limbus in glaucoma patients: in vivo confocal microscopy and
immunocytological study,” Investigative Opthalmology & Visual
Science, vol. 56, no. 3, pp. 2050–2058, 2015.
[11] P. Carpineto, L. Agnifili, M. Nubile et al., “Conjunctival and
corneal findings in bleb-associated endophthalmitis: an in vivo
confocal microscopy study,” Acta Ophthalmologica, vol. 89, no.
4, pp. 388–395, 2011.
[12] L. Mastropasqua, L. Agnifili, R. Mastropasqua et al., “In vivo
laser scanning confocal microscopy of the ocular surface in
glaucoma,”Microscopy andMicroanalysis, vol. 20, no. 3, pp. 879–
894, 2014.
[13] E. Villani, C. Baudouin, N. Efron et al., “In vivo confocal
microscopy of the ocular surface: from bench to bedside,”
Current Eye Research, vol. 39, no. 3, pp. 213–231, 2014.
[14] N. Efron, M. Al-Dossari, and N. Pritchard, “In vivo confocal
microscopy of the palpebral conjunctiva and tarsal plate,”
Optometry and Vision Science, vol. 86, no. 11, pp. E1303–E1308,
2009.
[15] A. Wei, J. Hong, X. Sun, and J. Xu, “Evaluation of age-related
changes in humanpalpebral conjunctiva andmeibomian glands
by in vivo confocal microscopy,”Cornea, vol. 30, no. 9, pp. 1007–
1012, 2011.
[16] E. Villani, V. Canton, F. Magnani, F. Viola, P. Nucci, and R.
Ratiglia, “The aging meibomian gland: an in vivo confocal
study,” Investigative Ophthalmology and Visual Science, vol. 54,
no. 7, pp. 4735–4740, 2013.
[17] D. A. Sullivan, B. D. Sullivan, M. D. Ullman et al., “Androgen
influence on the meibomian gland,” Investigative Ophthalmol-
ogy and Visual Science, vol. 41, no. 12, pp. 3732–3742, 2000.
[18] B. D. Sullivan, J. E. Evans, J. M. Cermak, K. L. Krenzer, M.
R. Dana, and D. A. Sullivan, “Complete androgen insensitivity
syndrome: effect on human meibomian gland secretions,”
Archives of Ophthalmology, vol. 120, no. 12, pp. 1689–1699, 2002.
[19] C.Auw-Haedrich andN. Feltgen, “Estrogen receptor expression
in meibomian glands and its correlation with age and dry-
eye parameters,” Graefe’s Archive for Clinical and Experimental
Ophthalmology, vol. 241, no. 9, pp. 705–709, 2003.
[20] M. M. Hom, J. R. Martinson, L. L. Knapp, and J. R. Paugh,
“Prevalence of meibomian gland dysfunction,” Optometry and
Vision Science, vol. 67, no. 9, pp. 710–712, 1990.
[21] A. Bodineau, M. Folliguet, and S. Se´guier, “Tissular senescence
and modifications of oral ecosystem in the elderly: risk factors
formucosal pathologies,”Current Aging Science, vol. 2, no. 2, pp.
109–120, 2009.
[22] E. M. Rocha, M. Alves, J. D. Rios, and D. A. Dartt, “The
aging lacrimal gland: changes in structure and function,”Ocular
Surface, vol. 6, no. 4, pp. 162–174, 2008.
[23] L. Agnifili, R. Mastropasqua, V. Fasanella et al., “In vivo
confocal microscopy of conjunctiva-associated lymphoid tissue
in healthy humans,” Investigative Ophthalmology and Visual
Science, vol. 55, no. 8, pp. 5254–5262, 2014.
[24] E.Villani, F.Magnani, F. Viola et al., “In vivo confocal evaluation
of the ocular surface morpho-functional unit in dry eye,”
Optometry and Vision Science, vol. 90, no. 6, pp. 576–586, 2013.
[25] E. Villani, F. Mantelli, and P. Nucci, “In-vivo confocal micros-
copy of the ocular surface: ocular allergy and dry eye,” Current
Opinion in Allergy and Clinical Immunology, vol. 13, no. 5, pp.
569–576, 2013.
[26] A. Kobayashi, T. Yoshita, and K. Sugiyama, “In vivo findings
of the bulbar/palpebral conjunctiva and presumed meibomian
glands by laser scanning confocal microscopy,” Cornea, vol. 24,
no. 8, pp. 985–988, 2005.
[27] E. M. Messmer, M. J. Mackert, D. M. Zapp, and A. Kampik, “In
vivo confocal microscopy of normal conjunctiva and conjunc-
tivitis,” Cornea, vol. 25, no. 7, pp. 781–788, 2006.
[28] E. M. Messmer, E. Torres Sua´rez, M. I. Mackert, D. M. Zapp,
and A. Kampik, “In vivo confocal microscopy in blepharitis,”
Klinische Monatsblatter fur Augenheilkunde, vol. 222, no. 11, pp.
894–900, 2005.
[29] Y. Matsumoto, E. A. Sato, O. M. A. Ibrahim, M. Dogru,
and K. Tsubota, “The application of in vivo laser confocal
microscopy to the diagnosis and evaluation ofmeibomian gland
dysfunction,”Molecular Vision, vol. 14, pp. 1263–1271, 2008.
[30] O. M. A. Ibrahim, Y. Matsumoto, M. Dogru et al., “The
efficacy, sensitivity, and specificity of in vivo laser confocal
microscopy in the diagnosis of meibomian gland dysfunction,”
Ophthalmology, vol. 117, no. 4, pp. 665–672, 2010.
[31] O. M. A. Ibrahim, Y. Matsumoto, M. Dogru et al., “In vivo con-
focal microscopy evaluation of meibomian gland dysfunction
in atopic-keratoconjunctivitis patients,” in Proceedings of the
64th Congress of Clinical Ophthalmology of Japan, Kobe, Japan,
November 2010.
8 BioMed Research International
[32] E. Villani, G. Ceresara, S. Beretta, F. Magnani, F. Viola, and R.
Ratiglia, “In vivo confocal microscopy of meibomian glands in
contact lens wearers,” Investigative Ophthalmology and Visual
Science, vol. 52, no. 8, pp. 5215–5219, 2011.
[33] E. Villani, S. Beretta, M. De Capitani, D. Galimberti, F. Viola,
and R. Ratiglia, “In vivo confocal microscopy of meibomian
glands in Sjo¨gren’s syndrome,” Investigative Ophthalmology and
Visual Science, vol. 52, no. 2, pp. 933–939, 2011.
[34] Y. Ban, Y. Ogawa, O. M. A. Ibrahim et al., “Morphologic
evaluation of Meibomian glands in chronic graft-versus-host
disease using in vivo laser confocal microscopy,” Molecular
Vision, vol. 17, pp. 2533–2543, 2011.
[35] Q. Le, J. Hong,W. Zhu, X. Sun, and J. Xu, “In vivo laser scanning
confocal microscopy of vernal keratoconjunctivitis,” Clinical
and Experimental Ophthalmology, vol. 39, no. 1, pp. 53–60, 2011.
[36] O. M. A. Ibrahim, Y. Matsumoto, M. Dogru et al., “In vivo con-
focal microscopy evaluation of meibomian gland dysfunction
in atopic-keratoconjunctivitis patients,”Ophthalmology, vol. 119,
no. 10, pp. 1961–1968, 2012.
[37] E. Villani, M. D. Strologo, F. Pichi et al., “Dry eye in vernal kera-
toconjunctivitis: a cross-sectional comparative study,”Medicine
(Baltimore), vol. 94, no. 42, article e1648, 2015.
[38] E. Villani, E. Garoli, V. Canton, F. Pichi, P. Nucci, andR. Ratiglia,
“Evaluation of a novel eyelid-warming device in meibomian
gland dysfunction unresponsive to traditional warm compress
treatment: an in vivo confocal study,” International Ophthalmol-
ogy, vol. 35, no. 3, pp. 319–323, 2014.
[39] Q. Wei, Q. Le, J. Hong, J. Xiang, A. Wei, and J. Xu, “In
vivo confocal microscopy of meibomian glands and palpebral
conjunctiva in vernal keratoconjunctivitis,” Indian Journal of
Ophthalmology, vol. 63, no. 4, pp. 327–330, 2015.
[40] L. Agnifili, V. Fasanella, C. Costagliola et al., “In vivo confocal
microscopy of meibomian glands in glaucoma,” British Journal
of Ophthalmology, vol. 97, no. 3, pp. 343–349, 2013.
[41] S. Stanek, “Meibomian gland status comparison between active
duty personnel and U.S. veterans,” Military Medicine, vol. 165,
no. 8, pp. 591–593, 2000.
[42] Y.Matsumoto, Y. Shigeno, E.A. Sato et al., “The evaluation of the
treatment response in obstructive meibomian gland disease by
in vivo laser confocal microscopy,” Graefe’s Archive for Clinical
and Experimental Ophthalmology, vol. 247, no. 6, pp. 821–829,
2009.
[43] Y. Qazi, A. Kheirkhah, C. Blackie et al., “In vivo detection of
clinically non-apparent ocular surface inflammation in patients
with meibomian gland dysfunction-associated refractory dry
eye symptoms: a pilot study,” Eye, vol. 29, no. 8, pp. 1099–1110,
2015.
[44] M. G. Cunniffe, R. Medel-Jime´nez, and M. Gonza´lez-Candial,
“Topical antiglaucoma treatment with prostaglandin analogues
may precipitate meibomian gland disease,” Ophthalmic Plastic
and Reconstructive Surgery, vol. 27, no. 5, pp. 128–129, 2011.
[45] R. Arita, K. Itoh, S. Maeda et al., “Comparison of the long-
term effects of various topical antiglaucoma medications on
meibomian glands,” Cornea, vol. 31, no. 11, pp. 1229–1234, 2012.
[46] R. Arita, K. Itoh, S. Maeda et al., “Effects of long-term topical
anti-glaucoma medications on meibomian glands,” Graefe’s
Archive for Clinical and Experimental Ophthalmology, vol. 250,
no. 8, pp. 1181–1185, 2012.
[47] InternationalDry EyeWorkShop, “Thedefinition and classifica-
tion of dry eye disease: report of the definition and classification
subcommittee of the international dry eye workshop,” The
Ocular Surface, vol. 5, pp. 75–92, 2007.
[48] A. Alhatem, B. Cavalcanti, and P. Hamrah, “In vivo confocal
microscopy in dry eye disease and related conditions,” Seminars
in Ophthalmology, vol. 27, no. 5-6, pp. 138–148, 2012.
[49] A. S. Bacon, S. J. Tuft, D. M. Metz et al., “The origin of
keratopathy in chronic allergic eye disease: a histopathological
study,” Eye, vol. 7, supplement, pp. 21–25, 1993.
[50] M. Dogru, C. Katakami, N. Nakagawa, K. Tetsumoto, and
M. Yamamoto, “Impression cytology in atopic dermatitis,”
Ophthalmology, vol. 105, no. 8, pp. 1478–1484, 1998.
[51] S. J. Tuft,D.M.Kemeny, J. K. G.Dart, andR. J. Buckley, “Clinical
features of atopic keratoconjunctivitis,” Ophthalmology, vol. 98,
no. 2, pp. 150–158, 1991.
[52] C. S. Forster and M. Calonge, “Atopic keratoconjunctivitis,”
Ophthalmology, vol. 97, no. 8, pp. 992–1000, 1990.
[53] M. J. Hogan, “Atopic keratoconjunctivitis,” Transactions of the
American Ophthalmological Society, vol. 50, pp. 265–281, 1952.
[54] M. Dogru, N. Okada, N. Asano-Kato et al., “Atopic ocular
surface disease: implications on tear function and ocular surface
mucins,” Cornea, vol. 24, no. 8, supplement, pp. S18–S23, 2005.
[55] L.Mastropasqua, L. Agnifili, R.Mastropasqua, andV. Fasanella,
“Conjunctival modifications induced by medical and surgical
therapies in patients with glaucoma,” Current Opinion in Phar-
macology, vol. 13, no. 1, pp. 56–64, 2013.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
